GlassScriptPhysician profile
Ogleh I Nesheiwat
NPI 1194809145
$9,909.62
in general payments reported to CMS, 2019-2025
46 companies · $1,143 in 2025
The $1,143 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,620 · 2020: $988 · 2021: $1,300 · 2022: $1,409 · 2023: $2,000 · 2024: $1,450 · 2025: $1,143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,592.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,150.09 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,038.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $810.65 | 2019-2025 | Farxiga, Breztri, Lokelma |
| Glaxosmithkline, LLC. | $632.22 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Abbvie INC. | $615.27 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $529.31 | 2021-2025 | Jardiance, Synjardy, Glyxambi |
| Otsuka America Pharmaceutical, INC. | $481.06 | 2022-2025 | Rexulti, Abilify Mycite |
| Abbott Laboratories | $476.42 | 2019-2025 | Freestyle Libre, Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $438.36 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $411.13 | 2019-2021 | |
| Pfizer INC. | $373.39 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $296.25 | 2021-2025 | |
| Medtronic, INC. | $295.06 | 2021-2025 | Minimed 780g, Minimed 630g, Inpen Smart Insulin Delivery System |
| Sanofi-Aventis U.S. LLC | $257.93 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $230.93 | 2019-2020 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ogleh Nesheiwat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.